Costello syndrome and related disorders

Current Opinion in Pediatrics

Volumn 19, Issue 6, 2007, Pages 636-644

  Quezada, Emilio ^a   Gripp, Karen W ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Hypertrophic cardiomyopathy; Myopathy; Rhabdomyosarcoma; Tachycardia

Indexed keywords

GENE PRODUCT; MITOGEN ACTIVATED PROTEIN KINASE;

CANCER SUSCEPTIBILITY; CARDIO FACIO CUTANEOUS SYNDROME; COGNITIVE DEFECT; CORRELATION ANALYSIS; COSTELLO SYNDROME; CRANIOFACIAL MALFORMATION; EMBRYO DEVELOPMENT; FAILURE TO THRIVE; GENE MUTATION; GENETIC IDENTIFICATION; GENOTYPE; HEART DISEASE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LEOPARD SYNDROME; MUTATION; NEUROFIBROMATOSIS; NOONAN SYNDROME; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ABNORMALITIES, MULTIPLE; CHILD; DEVELOPMENTAL DISABILITIES; DIAGNOSIS, DIFFERENTIAL; FACE; FACIES; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HEART DISEASES; HUMANS; LEOPARD SYNDROME; MAP KINASE SIGNALING SYSTEM; MENTAL RETARDATION; NEOPLASMS; NEUROFIBROMATOSIS 1; NOONAN SYNDROME; PHENOTYPE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RHABDOMYOSARCOMA; SKIN ABNORMALITIES; SYNDROME;

EID: 36348968826     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3282f161dc     Document Type: Review

References (54)

1. Gripp K, Lin A. Costello syndrome: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Seattle: University of Washington; 2006. Available at http://www.genetests.org. This is a clinically relevant and updated description of Costello syndrome. This website provides basic and detailed information on genetic disorders, including laboratory options for genetic testing.
2. Hennekam RCM. Costello syndrome: an overview. Am J Med Genet 2003; 117C:42-48.
3. Gripp KW. Tumor predisposition in Costello syndrome. Am J Med Genet 2005; 137C:72-77.
4. Gripp KW, Scott CI Jr, Nicholson L, et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet 2002; 108:80-87.
5. Rauen K. Cardio-facio-cutaneous syndrome: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Seattle: University of Washington; 2006. Available at http://www.genetests.org. This is a clinically relevant and updated description of CFC syndrome. This website provides basic and detailed information on genetic disorders, including laboratory options for genetic testing.
6. Allanson JE. Noonan syndrome: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Seattle: University of Washington; 2006. Available at http://www.genetests.org. This is a clinically relevant and updated description of Noonan syndrome. This website provides basic and detailed information on genetic disorders, including laboratory options for genetic testing.
7. O'Brien B, Lin A, Demmer L, et al. Toward a fetal phenotype of Costello syndrome. American College of Medical Genetics Meeting; 22-25 March 2007; Nashville.
8. Gregersen N, Viljoen D. Costello syndrome with growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations. Am J Med Genet 2004; 129A:171-175.
9. Alexander S, Ramadan D, Alkhayyat H, et al. Costello syndrome and hyperinsulinemic hypoglycemia. Am J Med Genet 2005; 139A:227-230.
10. Barreca A, Cotellessa M, Boschetti M, et al. The IGF system in a case of Costello syndrome. J Endocrinol Invest 2006; 29:261-264.
11. Delrue MA, Chateil JF, Arveiler B, Lacombe D. Costello syndrome and neurological abnormalities. Am J Med Genet 2003; 123A:301-305.
12. Gripp KW, Lin AE, Stabley DL, et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet 2006; 140A:1-7.
13. Axelrad ME, Glidden R, Nicholson L, Gripp KW. Adaptive skills, cognitive, and behavioral characteristics of Costello syndrome. Am J Med Genet 2004; 128A:396-400.
14. Axelrad ME, Nicholson L, Stabley DL, et al. Longitudinal assessment of cognitive characteristics in Costello syndrome. Am J Med Genet 2007 (in press).
15. White SM, Graham JM, Kerr B, et al. The adult phenotype in Costello syndrome. Am J Med Genet 2005; 136A:128-135.
16. Gripp KW, Lin AE, Nicholson L, et al. Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardiofacio-cutaneous syndrome from Costello syndrome. Am J Med Genet 2007; 143A:1472-1480.
17. Lin AE, Grossfeld PD, Hamilton RM, et al. Further delineation of cardiac abnormalities in Costello syndrome. Am J Med Genet 2002; 111:115-129.
18. Gripp KW, Kawame H, Viskochil DH, Nicholson L. Elevated catecholamine metabolites in patients with Costello syndrome. Am J Med Genet 2004; 128A:48-51.
19. Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS protooncogene cause Costello syndrome. Nat Genet 2005; 37:1038-1040.
20. Giehl K. Oncogenic Ras in tumor progression and metastasis. Biol Chem 2005; 386:193-205.
21. Estep A, Tidyman WE, Teitell MA, et al. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet 2005; 140A:8-16.
22. Kerr B, Delrue MA, Sigaudy S, et al. Genotype-phenotype correlation in Costello syndrome; HRAS mutation analysis in 43 cases. J Med Genet 2006; 43:401-405.
23. Sol-Church K, Stabley DL, Nicholson L, et al. Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat 2006; 27:736-741.
24. Van Steensel MA, Vreeburg M, Peels C, et al. Recurring HRAS mutation G12S in Dutch patients with Costello syndrome. Exp Dermatol 2006; 15:731-734.
25. Zampino G, Pantaleoni F, Carta C, et al. Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 2007; 28:265-272.
26. Rauen KA. HRAS and the Costello syndrome. Clin Genet 2007; 71:101-108.
27. Gripp KW, Stabley DL, Nicholson L, et al. Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet 2006; 140A:2163-2169. This is the first case report of somatic mosaicism in Costello syndrome.
28. Van der Burgt I, Kupsky W, Stassou S, et al. Myopathy caused by HRAS germline mutations - implications on disturbed myogenic differentiation in the presence of constitutive H-Ras activation. J Med Genet 2007; 44:459-462. The article provides novel information about myopathy caused by HRAS activation in Costello syndrome patients.
29. Roberts A, Allanson J, Jadico SK, et al. The cardiofaciocutaneous syndrome. J Med Genet 2006; 43:833-842.
30. Niihori T, Aoki Y, Narumi Y, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006; 38:294-296. One of the early reports on the mutations causing CFC syndrome.
31. Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006; 311:1287-1290. One of the early reports on the mutations causing CFC syndrome.
32. Narumi Y, Aoki Y, Niihori T, et al. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet 2007; 143A:799-807.
33. Rauen KA. Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype. Am J Med Genet 2006; 140A:1681-1683.
34. Al-Rahawan MM, Chute D, Sol-Church K, et al. Hepatoblastoma and heart transplantation in a patient with cardio-facio-cutaneous syndrome. Am J Med Genet 2007; 143A:1481-1488. This is the first report of a solid tumor in a patient with molecularly diagnosed CFC syndrome.
35. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29:465-468.
36. Chen Y, Takita J, Hiwatari M, et al. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 2006; 45:583-591.
37. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34:148-150.
38. Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007; 39:70-74. The article reports the identification of missense mutations in SOS1 in Noonan syndrome.
39. Tartaglia M, Pennacchio LA, Zhao C, et al. Gain-of function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007; 39:75-79. This article describes SOS1 mutations in Noonan syndrome.
40. Pandit B, Sarkozy A, Pennacchio LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007; 39:1007-1012.
41. Razzaque MA, Nishizawa T, Komoike Y, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007; 39:1013-1017.
42. Sarkozy A, Schirinzi A, Lepri F, et al. Clinical lumping and molecular splitting of LEOPARD and NF1/NF1-Noonan syndromes. Am J Med Genet 2007; 143A:1009-1011.
43. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006; 38:331-336.
44. Carta C, Pantaleoni F, Bocchinfuso G, et al. Germline missense mutations affecting KRAS isoforms B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 2006; 79:129-135.
45. Zenker M, Lehmann K, Schulz AL, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2007; 44:131-135. The phenotype of patients with KRAS germline alterations is reviewed in detail and differentiated from previously described syndromes.
46. Friedman JM. Neurofibromatosis 1: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Seattle: University of Washington; 2006. Available at http://www.genetests.org. This is a clinically relevant and updated description of neurofibromatosis. This website provides basic and detailed information on genetic disorders, including laboratory options for genetic testing.
47. Colley A, Donnai D, Evans DG. Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. Clin Genet 1996; 49:59-64.
48. Stevenson DA, Viskochil DH, Rope AF, Carey JC. Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype. Clin Genet 2006; 69:246-253.
49. Kratz CP, Niemeyer CM, Zenker M. An unexpected new role of mutant Ras: perturbation of human embryonic development. J Mol Med 2007; 85:223-231.
50. Kratz CP, Schubbert S, Bollag G, et al. Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders. Cell Cycle 2006; 5:1607-1611.
51. Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med 2006; 12:283-285. This article provides an excellent overview of the RAS pathway and its role in human development and carcinogenesis.
52. Ørstavik KH, Tangeraas T, Molven A, Prescott TE. Distal phalangeal creases - a distinctive dysmorphic feature in disorders of the RAS signaling pathway. Eur J Med Genet 2007; 50:155-158.
53. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308.
54. Kontaridis MI, Swanson KD, David FS, et al. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 2006; 281:6785-6792.